A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer (Q34733919)

4 August 2017

title

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer (English)

1 reference

cost-effectiveness analysis

4 August 2017

main subject

1 reference

inferred from title

cervix uterine cancer

1 reference

Nadia Demarteau

1

1 reference

4 August 2017

Bruno Detournay

2

1 reference

4 August 2017

Bertrand Tehard

3

1 reference

4 August 2017

Abdelkader El Hasnaoui

4

1 reference

4 August 2017

Baudouin Standaert

5

1 reference

4 August 2017

publication date

26 November 2010

1 reference

International Journal of Public Health

4 August 2017

published in

1 reference

4 August 2017

volume

56

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

153-162

1 reference

4 August 2017

cites work

HPV vaccine: Cervarix

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Modeling cervical cancer prevention in developed countries

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Sexual behaviour in context: a global perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Chapter 1: HPV in the etiology of human cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

The epidemiology of genital human papillomavirus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Cost-effectiveness of a potential vaccine for human papillomavirus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

The causal relation between human papillomavirus and cervical cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Roots and perspectives of contemporary papillomavirus research

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Meta-analysis of Pap test accuracy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

[Invasive cervical cancer treatment costs in France].

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3066388

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

26 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00038-010-0216-6

Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction

21 January 2018

1 reference

12 December 2020

Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear

1 reference

12 December 2020

Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus

1 reference

12 December 2020

Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security

1 reference

12 December 2020

[Epidemiology of HPV infection]

1 reference

12 December 2020

Cytopathology in France

1 reference

12 December 2020

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

1 reference

12 December 2020

[Cervical cancer screening and associated treatment costs in France]

1 reference

12 December 2020

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

12 December 2020

Cervical cancer screening in France

1 reference

12 December 2020

10.1007/S00038-010-0216-6

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference